In a breakthrough for paediatric HIV treatment in Uganda and across the region, Quality Chemical Industries Limited (QCIL) has unveiled a new, locally manufactured HIV medicine for children, combining the active ingredients Abacavir, Dolutegravir, and Lamivudine.
The launch, held at QCIL’s Luzira plant, coincided with the company’s 20th anniversary, marking two decades of advancing Uganda’s pharmaceutical manufacturing capacity.
Bridging the Gap in Paediatric HIV Care
Children living with HIV have long faced barriers to accessing appropriate treatment compared to adults. According to Uganda’s Ministry of Health, about 72,000 children under 15 are living with HIV, with only three-quarters on antiretroviral therapy and just half achieving viral suppression.
The newly launched paediatric combination drug is tailored specifically for children and simplifies treatment by reducing pill burden. Experts say the medicine will make adherence easier and improve long-term health outcomes for young patients.
Boosting Local Manufacturing and Regional Reach
The launch highlights Uganda’s growing capacity in local pharmaceutical production. QCIL, already a WHO-prequalified manufacturer of HIV/AIDS and malaria drugs, recently announced a US$36 million factory expansion to increase annual production from 1.4 billion to 2.4 billion tablets, while adding new lines for tuberculosis and injectable drugs.
With this innovation, QCIL aims not only to meet Uganda’s domestic demand but also to serve regional markets, reducing dependency on imported medicines and strengthening Africa’s healthcare supply chains.
Government Applauds QCIL’s Role
Deputy Speaker of Parliament Thomas Tayebwa, who officiated at the event, hailed QCIL as a model for industrialisation and public health impact.
“QCIL stands as a premier example of import substitution and industrial growth—this is a model we must replicate,” Tayebwa said.
Health Minister Dr Jane Ruth Aceng praised the innovation as a “turning point” in paediatric HIV care, noting that children had for long been “forgotten” in the country’s HIV response.
Transforming Uganda’s Fight Against HIV/AIDS
The new paediatric treatment is expected to deliver several benefits:
- Simplified adherence: Child-friendly formulation with fewer pills.
- Improved access: Locally produced drugs lower costs and ensure a steady supply.
- Regional impact: Potential to reach neighbouring African countries.
- Health system strengthening: Enhances Uganda’s self-sufficiency in essential medicines.
Looking Ahead
Experts note that challenges remain, including ensuring equitable distribution to remote areas, continued adherence support, and sustained investment in local pharmaceutical innovation.
Still, the unveiling marks a significant stride in Uganda’s journey toward universal access to quality healthcare and equitable treatment for all age groups.
As QCIL celebrates 20 years of service, the company reaffirmed its commitment to “providing affordable, quality medications for Africa, made in Africa.”
